Dishman Carbogen Amcis Ltd has reported a revenue of ₹660.76 crore for the second quarter ending September 30, 2025. This figure reflects a decrease compared to the previous quarter's revenue of ₹732.80 crore, showcasing a 19.5% drop year-over-year when compared to ₹795.69 crore reported in Q2 2024. The company's total income from operations also saw a decline, with net income from operations reported at ₹652.65 crore for the quarter. The Board of Directors approved these unaudited financial results during a meeting held on November 4, 2025.

In terms of expenses, Dishman Carbogen Amcis recorded a total of ₹630.22 crore, which represents a significant reduction from ₹691.48 crore in the previous quarter. Notably, the company's employee benefits expense amounted to ₹332.94 crore, marking an increase compared to the previous quarter. Despite the dip in revenue, the company achieved a net profit of ₹65.27 crore for the quarter, a notable improvement from ₹23.41 crore in Q1 2025 and ₹33.09 crore for the same quarter last year. This contrasts with the net loss of ₹44.48 crore reported for the entire fiscal year ending March 31, 2025.

Dishman Carbogen Amcis also provided a comprehensive view of its financial standing through its balance sheet, revealing total assets of ₹11,109.14 crore as of September 30, 2025. The company’s net profit reflects its resilience amid fluctuating revenues and expenses. With ongoing investments in operational capacities and strategic execution, Dishman Carbogen Amcis aims to navigate the challenges in the pharmaceutical industry while continuing to enhance shareholder value. The company’s stock is traded under the symbol DCAL on the National Stock Exchange of India.